Bicycle Therapeutics plc (BCYC)
$3.89+2.10%Close
BUYRECOVERY · day 5
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $270M
- Beta
- 1.68
- P/E (TTM)
- -1.39
- Short % float
- 5.37%
- Days to cover
- 8.7
- SI change
- -0.9%
- 1W
- +15.09%
- 1M
- +1.57%
- vs SPY 1W
- +13.93%
- vs SPY 1M
- -1.43%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 16
- VALUE
- 21
- GROWTH
- 43
- GARP
- 7
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-19.9%
REV YoY-
ROE-33.2%
EPS YoY-
ROA-31.4%
GROSS100
OP-344
NET-311
[VALUATION]
P/E TTM-1.39
P/E FWD-
SECTOR PE20.47
INDUSTRY PE13.95
P/B0.52
P/FCF-
EV/EBITDA1.27
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E2.68
ALTMAN Z-
CURR RATIO12.08
ND/EBITDA-
BETA1.68
Company news
FAQ
- What is LOPJLB’s current signal on BCYC?
- LOPJLB’s latest quantitative signal on Bicycle Therapeutics plc (BCYC) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is BCYC in?
- Bicycle Therapeutics plc (BCYC) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Bicycle Therapeutics plc (BCYC) do?
- Bicycle Therapeutics plc, founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently lacking effective treatments. The company's leading investigational product, BT1718, is a Bicycle Toxin Conjugate (BTC) that is undergoing Phase I/IIa clinical trials. This candidate is engineered…